AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Edwards Lifesciences Corp (NYSE:EW)
86.02 USD
-1.640 1.871%Sponsored Reports
Loading...
| Previous Close (in USD) | 87.66 |
|---|---|
| Change | -1.640 1.871% |
| 52 W H/L (in USD) | 87.890/72.300 |
| EBITDA (in USD) | 1794.5M |
| PE Ratio | 45.03 |
| Volume | 4905490 |
| Diluted Eps TTM | 1.77 |
| Total Assets (in USD) | 13697.2M |
|---|---|
| Total Liabilities (in USD) | 3359.6M |
| Revenue TTM (in USD) | 6067.6M |
| Cash (in USD) | 2938.5M |
| Market Cap (in USD) | 46,295.568 M |
| Revenue Per Share TTM | 10.376 |
| Gross Profit TTM (in USD) | 4733.4M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Edwards Lifesciences Corp
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Employees: 16000
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Michael A. Mussallem | Chairman & CEO | 1953 |
| 2. | Mr. Scott B. Ullem | Corp. VP & CFO | 1967 |
| 3. | Mr. Donald E. Bobo Jr. | Corp. VP of Strategy & Corp. Devel. | 1962 |
| 4. | Mr. Larry L. Wood | Corp. VP of Transcatheter Aortic Valve Replacement | 1966 |
| 5. | Mr. Jean-Luc Lemercier | Corp. VP of Europe, Middle East, Africa, Canada & Latin America | 1957 |
| 6. | Dr. Todd J. Brinton | Corp. VP of Advanced Technology & Chief Scientific Officer | NA |
| 7. | Mark Wilterding | VP of Investor Relations | NA |
| 8. | Mr. Arnold A. Pinkston | Corp. VP & Gen. Counsel | 1959 |
| 9. | Mr. Dirksen J. Lehman | Corp. VP of Public Affairs | NA |
| 10. | Ms. Christine Z. McCauley | Corp. VP of HR | 1965 |
Peers
Sector: Healthcare
Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
ABT
Abbott Laboratories |
+0.020 0.023% | 87.195 | 25.970 | 17.241 | 3.570 | 3.200 | 3.805 | 16.753 |
|
SYK
Stryker Corporation |
+1.700 0.580% | 295 | 44.070 | 24.938 | 5.509 | 6.118 | 6.050 | 25.731 |
|
MDT
Medtronic PLC |
+4.200 5.695% | 77.12 | 26.600 | 15.873 | 3.354 | 2.083 | 3.897 | 14.117 |
|
BSX
Boston Scientific Corp |
+0.010 0.021% | 47.81 | 31.490 | 17.241 | 4.407 | 3.650 | 4.878 | 19.194 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | 1272.9M | 1548.1M | 1598.1M | 1767.4M | 1702M |
| Minority Interest | 4.1M | 4.9M | 3M | - | - |
| Net Income | 1073.5M | 4174.6M | 1402.4M | 1521.9M | 1503.1M |
| Selling General Administrative | 2085.2M | 1789.2M | 1755.6M | 1567.6M | 1493.7M |
| Gross Profit | 4740.7M | 4322M | 4625M | 4302M | 3983.6M |
| Reconciled Depreciation | 156.6M | 155.2M | 143.6M | 139.6M | 134.8M |
| Ebit | 1272.9M | 1567.9M | 1534.1M | 1748.5M | 1348.5M |
| Ebitda | 1429.5M | 1723.1M | 1534.1M | 1829.9M | 1483.3M |
| Depreciation And Amortization | 156.6M | 155.2M | 144.9M | 81.4M | 134.8M |
| Operating Income | 1636.2M | 1378.7M | 1534.1M | 1748.5M | 1348.5M |
| Other Operating Expenses | 4431.4M | 4060.8M | 4276.2M | 3593.2M | 3645.7M |
| Interest Expense | 20.4M | 19.8M | 17.6M | 19.2M | 18.4M |
| Tax Provision | 216.9M | 152.1M | 207.6M | 245.5M | 198.9M |
| Interest Income | 148.4M | 120.3M | 67.2M | 16.3M | 1M |
| Net Interest Income | 148.4M | 100.5M | 40.7M | 16.3M | -1M |
| Income Tax Expense | 216.9M | 152.1M | 198.7M | 245.5M | 198.9M |
| Total Revenue | 6067.6M | 5439.5M | 6004.8M | 5382.4M | 5232.5M |
| Total Operating Expenses | 3104.5M | 2943.3M | 2896.4M | 2512.8M | 2396.8M |
| Cost Of Revenue | 1326.9M | 1117.5M | 1379.8M | 1080.4M | 1248.9M |
| Total Other Income Expense Net | -363.3M | 169.4M | 64M | 18.9M | 353.5M |
| Net Income From Continuing Ops | 1056M | 1396M | 1428.1M | 1521.9M | 1503.1M |
| Net Income Applicable To Common Shares | 1073.5M | 4174.6M | 1402.4M | 1521.9M | 1503.1M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 13697.2M | 13055.3M | 9363.2M | 8292.5M | 8502.6M |
| Intangible Assets | 1128.2M | 1176.6M | 399.4M | 285.2M | 323.6M |
| Other Current Assets | 473.8M | 495.4M | 671.3M | 195.9M | 237.1M |
| Total Liab | 3359.6M | 2992.4M | 2643.8M | 2485.8M | 2666.7M |
| Total Stockholder Equity | 10337.6M | 9998.4M | 6650M | 5806.7M | 5835.9M |
| Other Current Liab | 1534.5M | 856M | 879.4M | 311M | 3.9M |
| Common Stock | 658.7M | 654.8M | 650.5M | 646.3M | 642M |
| Capital Stock | 658.7M | 654.8M | 650.5M | 646.3M | 642M |
| Retained Earnings | 14240.5M | 13167M | 8992.4M | 7590M | 6068.1M |
| Good Will | 1768.6M | 1776.7M | 1145.1M | 1164.3M | 1167.9M |
| Other Assets | 1379.8M | 1724.5M | 1218.3M | 783.1M | 357.5M |
| Cash | 2938.5M | 3045.2M | 1132.3M | 769M | 862.8M |
| Cash And Equivalents | 2938M | 3045.2M | 1144M | 769M | 862.8M |
| Total Current Liabilities | 1813.7M | 1505.2M | 1195.4M | 1022.4M | 1032.3M |
| Current Deferred Revenue | 27.2M | 53.7M | 953.9M | 484M | 798.4M |
| Net Debt | -2233.1M | -2345.2M | -447.2M | -77.7M | -172.5M |
| Short Term Debt | 24.5M | 23.4M | 22.9M | 25.5M | 25.5M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 705.4M | 700M | 685.1M | 691.3M | 690.3M |
| Other Stockholder Equity | -4323.3M | -3578.9M | -2750.1M | -2174.7M | -716.5M |
| Property Plant Equipment | 1914.6M | 1784.2M | 1843.4M | 1725.1M | 1638.7M |
| Total Current Assets | 6738.9M | 6285.4M | 4035.7M | 3095.8M | 3180.7M |
| Long Term Investments | 278.6M | 307.9M | 583.9M | 1239M | 1834.2M |
| Short Term Investments | 1288.3M | 930.7M | 500.5M | 446.3M | 604M |
| Net Receivables | 912.1M | 727.4M | 828.1M | 699.1M | 664.9M |
| Long Term Debt | 598.3M | 597.7M | 597M | 596.3M | 595.7M |
| Inventory | 1126.2M | 1086.7M | 903.5M | 875.5M | 726.7M |
| Accounts Payable | 227.5M | 197.4M | 186.6M | 201.9M | 204.5M |
| Accumulated Other Comprehensive Income | -238.3M | -244.5M | -242.8M | -254.9M | -157.7M |
| Non Currrent Assets Other | 234.9M | 732.4M | 774.3M | 299.1M | 110.8M |
| Non Current Assets Total | 6958.3M | 6769.9M | 5327.5M | 5196.7M | 5321.9M |
| Capital Lease Obligations | 107.1M | 102.3M | 97.9M | 95M | 94.6M |
| Long Term Debt Total | 598.3M | 597.7M | 597M | 596.3M | 595.7M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | -282.1M | 2312.9M | 254.4M | 252.3M | -1335.2M |
| Total Cashflows From Investing Activities | -712.9M | 2312.9M | 173.8M | 252.3M | -1722.5M |
| Total Cash From Financing Activities | -956.8M | -983M | -711M | -1584.5M | -356.3M |
| Net Income | 1069.4M | 4169.7M | 1402.4M | 1521.9M | 1503.1M |
| Change In Cash | -119.3M | 1910.8M | 375.4M | -94.8M | -332.8M |
| Begin Period Cash Flow | 3058.8M | 1148M | 772.6M | 867.4M | 1200.2M |
| End Period Cash Flow | 2939.5M | 3058.8M | 1148M | 772.6M | 867.4M |
| Total Cash From Operating Activities | 1595.2M | 542.3M | 895.8M | 1218.2M | 1732.1M |
| Depreciation | 156.6M | 155.2M | 144.9M | 139.6M | 134.8M |
| Other Cashflows From Investing Activities | -195.7M | 3745.3M | -75M | 517.1M | -61.5M |
| Dividends Paid | - | - | 169.9M | - | - |
| Change To Inventory | 50.7M | -256.1M | -289M | -213.4M | 19M |
| Sale Purchase Of Stock | -893.4M | -1159.4M | -879.6M | -1727.1M | -512.8M |
| Other Cashflows From Financing Activities | -237.5M | 176.4M | 168.9M | 142.8M | 163.5M |
| Capital Expenditures | 260.2M | 252.4M | 266.3M | 264.8M | 329.8M |
| Change In Working Capital | 154.6M | -259.3M | -526.3M | -421.4M | 145.3M |
| Other Non Cash Items | 174.1M | -3362.2M | 7.5M | 105.8M | -119M |
| Free Cash Flow | 1335M | 289.9M | 629.5M | 953.4M | 1402.3M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 2 months ago | 18446396 |
| 2. | Vanguard Health Care Inv | 5 months ago | 14972830 |
| 3. | Vanguard 500 Index Investor | 2 months ago | 14775993 |
| 4. | Vanguard Mid Cap Index Institutional | 2 months ago | 12546778 |
| 5. | iShares Core S&P 500 ETF | 2 months ago | 7458826 |
| 6. | Fidelity 500 Index | 3 months ago | 7385045 |
| 7. | State Street® SPDR® S&P 500® ETF | 2 months ago | 6750798 |
| 8. | Vanguard Value Index Inv | 2 months ago | 5367927 |
| 9. | Vanguard Mid-Cap Growth ETF | 2 months ago | 4417623 |
| 10. | State Street®HlthCrSelSectSPDR®ETF | 2 months ago | 4241382 |
| 11. | JPM US Equity-MA | 2 months ago | 3725474 |
| 12. | JPMorgan US Equity L | 3 months ago | 3585514 |
| 13. | Vanguard Institutional Index I | 2 months ago | 3269441 |
| 14. | Harbor Capital Appreciation Instl | 2 months ago | 3234566 |
| 15. | BGF World Healthscience A2 | 5 months ago | 3152909 |
| 16. | State St S&P 500® Indx SL Cl III | 2 months ago | 3097720 |
| 17. | Ninety One Global Franchise | 5 months ago | 2971955 |
| 18. | Ninety One GSF Glb Frchs I Acc USD | 5 months ago | 2971955 |
| 19. | UniGlobal | 3 months ago | 2826408 |
| 20. | Vanguard Institutional 500 Index Trust | 2 months ago | 2620983 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Group Inc | 5 months ago | 70079435 |
| 2. | BlackRock Inc | 8 months ago | 54294173 |
| 3. | JPMorgan Chase & Co | 8 months ago | 50117052 |
| 4. | State Street Corp | 8 months ago | 25619632 |
| 5. | Wellington Management Company LLP | 5 months ago | 21793949 |
| 6. | Bank of New York Mellon Corp | 8 months ago | 19010227 |
| 7. | FMR Inc | 5 months ago | 16582547 |
| 8. | Jennison Associates LLC | 5 months ago | 13780515 |
| 9. | Geode Capital Management, LLC | 5 months ago | 12784902 |
| 10. | NORGES BANK | 5 months ago | 9427396 |
| 11. | Ninety One UK Limited | 5 months ago | 7734946 |
| 12. | DZ BANK AG Deutsche Zentral-Genossenschaftsbank Frankfurt am Main | 5 months ago | 7732010 |
| 13. | Brown Advisory Holdings Inc | 5 months ago | 7332126 |
| 14. | Morgan Stanley - Brokerage Accounts | 8 months ago | 6509350 |
| 15. | Millennium Management LLC | 5 months ago | 6080938 |
| 16. | Northern Trust Corp | 8 months ago | 6040645 |
| 17. | Marshall Wace Asset Management Ltd | 5 months ago | 5925627 |
| 18. | UBS Asset Mgmt Americas Inc | 8 months ago | 5584646 |
| 19. | Deutsche Bank AG | 5 months ago | 5578796 |
| 20. | Wellcome Trust Ltd | 5 months ago | 4800000 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...